Introduction {#Sec1}
============

Coronaviruses (CoVs) are enveloped, positive-sense RNA viruses belonging to the subfamily *Coronavirinae* and order *Nidovirales* (Huang et al. [@CR25]). CoVs have a common genome organization and are commonly categorized as alpha CoVs, beta CoVs, gamma CoVs, and delta CoVs on the basis of genomic structures and phylogenetic relationships. In these CoVs, transmission of alpha CoVs and beta CoVs is restricted to mammals and induces respiratory illness in humans, while gamma CoVs and delta CoVs are known to affect birds and mammals (Song et al. [@CR51]). Even though, most CoV infections are mild, but the outbreaks of the two beta CoVs, i.e., Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), have caused more than 10,000 combined cases and 1600 deaths in last 20 years (Skariyachan et al. [@CR50]). The incubation period of MERS and SARS is given as 2--13 and 2--14 days, respectively, the progression of infection is rapid with MERS-CoV as compared to SARS-CoV, and the reported mortality rates were 34% and 10%, respectively (Chen et al. [@CR13]; Rasmussen et al. [@CR43]). CoVs are zoonotic in nature, which means these viruses are transmitted between animals and humans. In the same way, SARS and MARS were reported to transmit in humans from civet cats and camel, respectively (Shehata et al. [@CR49]). Human-to-human transmission of SARS and MARS is also reported via close personal contact with infected patients. In 2012, MERS emerged as global heath challenge in countries near the Arabian Peninsula. As of July 31, 2019, 2458 laboratory-confirmed MERS cases and 848 deaths were reported where around 80% of these cases have been reported only in Saudi Arabia (Zheng et al. [@CR64]). In 2003, SARS-CoV was originated in southern China and transmitted to Hong Kong and 29 other countries with high human morbidity, leading to 8098 confirmed cases and 774 deaths (Hui and Zumla [@CR26]).

SARS-CoV-2 has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India (Li et al. [@CR35]). The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020 (ProMED-mail [@CR42]). SARS-CoV-2 and SARS are clinically similar, and recent studies have shown that SARS-CoV-2 is closely related to SARS-CoV (Kumar et al. [@CR31]). The cause and spread of SARS-CoV-2 outbreak are still unclear. Preliminary research has found positive samples for WN-CoV in the wholesale market of Huanan seafood in Wuhan City, but some patients confirmed by the laboratory have not reported visiting this area (Centers for Diseases Control and Prevention (CDC) [@CR10]). Evidence is still emerging; however, information to date shows that transmission from human to human occurs. SARS-CoV-2 infection in patients leads to pneumonia-like symptoms such as fever and difficulty in breathing with radiographs showing invasive pneumonic infiltrates in few cases. The evolution of novel CoVs has been shown to be associated with RNA recombination with the existing CoVs (Andersen et al. [@CR4]). The coronavirus (SARS-CoV-2, MERS, and SARS) infection initially spreads in adults, and the reported symptoms are fever, headache, vomiting, chills, dyspnea, nausea, sore throat, coughing up blood, shortness of breath, myalgia, diarrhea, and malaise (Table [10.1](#Tab1){ref-type="table"}). Severe infection leads to pneumonia, acute respiratory distress syndrome (ARDS), and sometimes multi-organ failure (Paules et al. [@CR40]). Coronavirus infection leads to thrombocytopenia, lymphopenia, and leukopenia with elevated levels of lactate dehydrogenase and liver enzymes (Arabi et al. [@CR5]).Table 10.1Epidemiology and characteristics of 2019-nCoV, MERS-CoV and SARS-CoVCharacteristics2019-nCoVMERS-CoVSARS-CoV*GenusBeta-CoVs, lineage BBeta-CoVs, lineage CBeta-CoVs, lineage B*Intermediary hostMalayan pangolinsDromedary camelPalm civetNatural reservoirBatBatBatOriginWuhan City, Hubei Province of ChinaArabian PeninsulaGuangdong Province, ChinaConfirmed cases245,922 (as of March 20, 2020)2458 (July 31, 2019)8098Total deaths10,048 (as of March 20, 2020)848774Affected countries168 (as of March 20, 2020)2729Transmission patternsFrom animal to human; from human to humanFrom animal to human; from human to humanFrom animal to human; from human to humanThe predominant receptorCellular protease TMPRSS2 and angiotensin-converting enzyme 2Human dipeptidyl peptidase 4 (DPP4 or CD26)Human angiotensin-converting enzyme 2 (ACE2)Cell line susceptibilityRespiratory tractRespiratory tract, intestinal tract, genitourinary tract, liver, kidney, neurons, monocyte, T lymphocyte and histiocytic cell linesRespiratory tract; kidney; liverViral replication efficiencyVery highHighLesser compared to MERS-CoVLength of nucleotides29,89130,11929,727Open reading frames (ORFs)121111Structural protein444Spike protein (length of amino acids)127313531255Non-structural proteins (NSPs)16165Accessory proteins658A characteristic gene order5′-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′5′-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′5′-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′

Treatment of Novel Coronavirus SARS-CoV-2 Infection {#Sec2}
===================================================

According to the World Health Organization (WHO), there is no existing data from randomized clinical trials to advocate any specific anti-nCoV therapy for patients either suspected or diagnosed with SARS-CoV-2. Unlicensed treatments can only be given in the circumstance of ethically approved clinical trials or under the Monitored Emergency Use of Unregistered Interventions System (MEURI), with strict supervision (World Health Organization [@CR61]). However, researchers have tested a number of FDA-approved drugs against SARS-CoV-2 infection, and these drugs have shown promising antiviral activity in both cell culture and animal models. Some of these drugs are also in clinical trial for SARS-CoV-2 (Li and De Clercq [@CR33]). In the past 2 months, drugs from various classes such as nucleoside analogs, protease inhibitors, and host-targeted agents have been tested to discover an authorized antiviral agent against SARS-CoV-2 infection (Table [10.2](#Tab2){ref-type="table"}). The National Medical Products Administration of China has recently approved fapilavir as the first antiviral medication for the treatment of SARS-CoV-2.Table 10.2List of drugs that have antiviral activity compounds against SARS-CoV-2Antiviral agentsDrug targetsReported mechanism of action*Virus-based treatment approaches*FavipiravirRdRpInhibits RdRpRibavirinRdRpInhibits viral RNA synthesis and mRNA cappingPenciclovirRdRpInhibits RdRpRemdesivir (GS-5734)RdRpTerminates the non-obligate chainLopinavir3CLproInhibits 3CLproRitonavir3CLproInhibits 3CLproDarunavir and cobicistat3CLproInhibits 3CLproASC09F (HIV protease inhibitor)3CLproInhibits 3CLproNafamostatSpike glycoproteinInhibits spike-mediated membrane fusionGriffithsinSpike glycoproteinInhibits spike-mediated membrane fusionArbidol (umifenovir)----Oseltamivir----*Host-based treatment approaches*Recombinant interferonsInterferon responseExogenous interferonsChloroquineEndosomal acidificationA lysosomotropic base that appears to disrupt intracellular trafficking and viral fusion eventsNitazoxanideInterferon responseInduces the host innate immune response to produce interferons by the host's fibroblasts and protein kinase R (PKR) activation

Approved Nucleoside Analogs {#Sec3}
---------------------------

At present, two approved nucleoside analogs (ribavirin and favipiravir) demonstrated antiviral activity against SARS-CoV-2 infection (Wang et al. [@CR56]). Nucleoside analogs have efficacy to target RNA-dependent RNA polymerase and inhibit the replication process in a broad range of RNA viruses including beta coronaviruses. Ribavirin was originally licensed for the treatment of HCV (hepatitis C virus) and RSV (respiratory syncytial virus). Ribavirin was also clinically evaluated against MERS and SARS coronaviruses, but the efficacy of the drug is uncertain and associated with severe side effects such as anemia and hypoxia at high doses (Arabi et al. [@CR6]). Similarly, ribavirin was also evaluated against SARS-CoV-2 infection, but the antiviral property of drugs is still not well established against the SARS-CoV-2. In addition, after oral administration, the drug was rapidly absorbed via sodium-dependent nucleoside transporters into the gastrointestinal tract. The drug has oral bioavailability around 64% with large volume of distribution. Drugs such as acetaminophen, acetazolamide, aspirin, acrivastine, and acyclovir are known to decrease the excretion rate that leads to the higher serum level of ribavirin. Similarly, coadministration of abacavir may increase the hepatotoxicity of ribavirin. Favipiravir (T-705) was initially authorized for the treatment of influenza. In addition, it is reported that favipiravir is also effective against a number of RNA viruses such as Ebola, Nipah, and enterovirus. Similarly, favipiravir demonstrates efficacy against SARS-CoV-2, and currently the drug is in randomized trials with interferon-α and baloxavir marboxil for SARS-CoV-2 infection (Li and De Clercq [@CR33]). The drug is well absorbed after oral administration in the gastrointestinal tract (98% bioavailability) and metabolized in liver, and the metabolites are excreted in urine. Favipiravir is contraindicated in pregnancy due to its teratogenic effect. Favipiravir also decreases the excretion of angiotensin-converting enzyme inhibitors such as captopril.

Experimental Nucleoside Analogs {#Sec4}
-------------------------------

Unlike the approved nucleoside analogs, two experimental nucleoside analogs remdesivir (GS-5734) and galidesivir (BCX4430) were also investigated against SARS-CoV-2 infection. Remdesivir and Galidesivir are adenine derivatives which demonstrate broad-spectrum antiviral activity in cell cultures and animal models against RNA viruses such as MERS and SARS (Agostini et al. [@CR1]; Sheahan et al. [@CR48]; Warren et al. [@CR58]). Recently, it is shown that the drug inhibited SARS-CoV-2 by integrating into nascent viral RNA chains that lead to premature termination of viral RNA chains (Wang et al. [@CR56]). Remdesivir is presently in clinical trial for Ebola and SARS-CoV-2 infection (Li and De Clercq [@CR33]).

Approved Protease Inhibitors {#Sec5}
----------------------------

Drugs such as disulfiram, lopinavir, and ritonavir have antiviral activity against human coronaviruses. Disulfiram was primarily used for the management of alcohol dependence, and it is reported that the drug also inhibits the papain-like protease of MERS and SARS in cell line models (Agostini et al. [@CR1]). In addition, lopinavir and ritonavir are the HIV protease inhibitors that also have efficacy against 3-chymotrypsin-like protease of MERS and SARS (Sheahan et al. [@CR48]; Kim et al. [@CR29]; Chan et al. [@CR11]). However, the mechanism of action of these protease inhibitors is still controversial. At present, lopinavir and ritonavir are in clinical trial in patients infected with SARS-CoV-2, and the results demonstrate that lopinavir--ritonavir treatment fails to reduce mortality or throat viral RNA load in patients with Covid-19 (Cao et al. [@CR9]). In the same way, nafamostat and griffithsin demonstrated inhibitory activity against spike glycoprotein of coronaviruses (Wang et al. [@CR56]; Barton et al. [@CR7]; O'Keefe et al. [@CR38]).

Host-Targeted Strategies {#Sec6}
------------------------

Several immune modulator drugs such as chloroquine, nitazoxanide, and ribavirin in combination of PEGylated interferon alfa-2a and -2b have shown inhibitory action against SARS-CoV-2 infection (Li and De Clercq [@CR33]). A recent study has shown that chloroquine is more effective to prevent SARS-CoV-2 infection in cell culture model compared to other tested drugs and also in an open-label trial for the treatment of SARS-CoV-2 infection in patients (Fig. [10.1](#Fig1){ref-type="fig"}) (Wang et al. [@CR56]).Fig. 10.1Investigational treatment approaches for COVID-19 infection

Early Supportive Therapy for SARS-CoV-2 Infection {#Sec7}
-------------------------------------------------

Patients with severe acute respiratory infection should be closely monitored for clinical signs and symptoms like sepsis and rapid respiratory failure to provide immediate supportive treatment in case of severe infection. Supplemental oxygen therapy must be provided in case of shock, hypoxemia, severe acute respiratory infection, and respiratory distress. Similarly, fluid and electrolyte balance should be maintained in infected patients. Antimicrobial agents should be given for the management of pathogen-associated severe acute respiratory infections. The administration of systemic corticosteroids should be avoided in case of viral pneumonia and patients with acute respiratory distress syndrome (World Health Organization [@CR62]).

Treatment of MERS-CoV and SARS-CoV Infections {#Sec8}
=============================================

In view of the high mortality rate of MERS-CoV and SARS-CoV infections, there are no licensed antiviral agents or vaccines available to date for successful disease control during outbreaks (Shahani et al. [@CR47]). Although, various therapeutic alternatives have been given for the management of infection such as antiviral drugs (ribavirin, lopinavir, and ritonavir), convalescent plasma, corticosteroids, monoclonal antibodies, intravenous immunoglobulin, and repurposing of existing clinically FDA-approved drugs (Totura and Bavari [@CR53]). The effectiveness of these drugs is not well established and given as symptomatic treatment to control the severity of infection. However, a retrospective analysis reported that ribavirin alone or in combination with interferon-alpha (IFN-ἀ) or lopinavir or ritonavir showed increase in survival compared to patients taking supportive care and corticosteroids against MERS-CoV infection (Falzarano et al. [@CR22]; Chu et al. [@CR18]; Chiou et al. [@CR16]; Loutfy et al. [@CR36]). In the same way, several studies have reported that ribavirin in conjugation with fluoroquinolones and corticosteroids did not demonstrate efficacy in patients with SARS-CoV infection (Table [10.3](#Tab3){ref-type="table"}) (Al-Tawfiq et al. [@CR3]; Omrani et al. [@CR39]; Spanakis et al. [@CR52]; Leong et al. [@CR32]; Muller et al. [@CR37]; Ward et al. [@CR57]; Zhao et al. [@CR63]). Nevertheless, it is concluded that ribavirin alone or in combination with other drugs fails to improve patient outcome against both MERS-CoV and SARS-CoV infections and is associated with adverse effects such as decreased hemoglobin levels, hemolytic anemia, hypoxemia, and metabolic abnormalities. In addition to ribavirin, interferons are also associated with psychiatric disturbances, neutropenia, and systemic adverse effects (Al-Dorzi et al. [@CR2]). Drug repurposing is an eye-catching alternative approach for discovering newer drugs during the virus epidemics for a number of viral infections because various measures are typically skipped during the initial phase of drug design. Recently, researchers have investigated the antiviral potential of various approved drugs as first-line of defense against the newly emerging infectious agents. Repurposing of pharmaceutical agents could be an effective arm to develop potential therapeutics for SARS-CoV-2, MERS-CoV, and SARS-CoV infection (Dyall et al. [@CR21]). The drugs from various classes such as antidiarrheal agents, antimalarial agents, cyclophilin inhibitors, interferons, kinase inhibitors, neurotransmitter inhibitors, anticholinergics, nucleic acid synthesis inhibitors, protease inhibitors, protein synthesis inhibitors, selective estrogen receptor modulators, and sterol metabolism inhibitors have demonstrated in vitro and in vivo antiviral efficacy against MERS-CoV and SARS-CoV infection (Table [10.4](#Tab4){ref-type="table"}) (Dyall et al. [@CR20], [@CR21]; de Wilde et al. [@CR59], [@CR60]; Hart et al. [@CR23]; Cinatl et al. [@CR19]; Kindrachuk et al. [@CR30]; Cheng et al. [@CR15]; Saijo et al. [@CR44]; Zhou et al. [@CR65]; Cao et al. [@CR8]).Table 10.3Drug regimens used for the treatment of MERS and SARS-CoV infectionTreatmentOutcome*MERS-CoV infection*Ribavirin (oral/IV)IFN-ἀ 2bCorticosteroidsLate treatment administration. Disease progression delayed and all patients diedRibavirin (oral/IV)PEGylated IFN-ἀ (IV)± CorticosteroidsTreatment was given 0--8 days after diagnosisSignificant decreases in hemoglobin and absolute neutrophil count (baseline count lower in treatment group) were also reportedRibavirin (oral/IV)Lopinavir/ritonavirIFN-ἀ-2bNo detectable viral RNA in serum after 2 days of therapyRibavirin discontinued due to jaundice, hyperbilirubinemiaPatients died with septic shock in 2 months*SARS-CoV infection*Ribavirin (oral/IV)Antibiotics± Corticosteroids± ImmunoglobulinNo increased positive outcome with ribavirin compared to controlsIncreased risk of anemia, hypomagnesemia, hypoxia, or bradycardia with ribavirin compared to ribavirin-naive patientsRibavirin (oral/IV)Lopinavir/ritonavir± CorticosteroidsFatality or acute respiratory distress syndrome (ARDS) was reduced significantly from 28.8% to 2.4%IFN-alfacon-1± Corticosteroids± AntibioticsIncreased oxygen saturationIncreased clearance of lung abnormalitiesSlight increase in creatinine kinase concentrationsFluoroquinolone (IV)Azithromycin (IV)IFN-α (IM)± Corticosteroids± Immunoglobulins± Thymic peptides/proteinsNo increased positive outcomeQuinolone (IV)Azithromycin (IV)± IFN-α± CorticosteroidsNo increased positive outcomeLevofloxacinAzithromycin± IFN-α± CorticosteroidsIncreased survivalIncreased clearance of lung abnormalitiesTable 10.4List of drugs with in vitro and in vivo antiviral activity against MERS-CoV and SARS-CoVDrugsClassMechanism of actionLoperamideAntidiarrheal agentsUnknownChloroquine, amodiaquine, mefloquineAntimalarial agentsChloroquine targets the type II transmembrane serine protease of MERS-CoVFor SARS-CoV, chloroquine has also been attributed to a deficit in glycosylation of the receptor angiotensin-converting enzyme 2Cyclosporine ACyclophilin inhibitorsUnknownIFN-ἀ, β1a, γ, IFN-ἀ 2bInterferonsInhibits replication of MERS-CoV and SARS-CoVImatinib, dasatinib, selumetinib, trametinib, sirolimusKinase inhibitorsImatinib and dasatinib act as entry inhibitor for both MERS and SARSSelumetinib and trametinib block the entry and replication of MERS-CoV via targeting ERK/MAPK signaling pathway. Sirolimus reduced MERS-CoV infection by \~60% via targeting mTOR signaling pathwayChlorpromazine, triflupromazine, thiethylperazine, promethazine fluphenazine, astemizole, chlorphenoxamine, fluspirileneNeurotransmitter inhibitorsChlorpromazine inhibits virus entry, whereas antiviral mechanism of other listed drugs was still not clearly understoodBenztropineAnticholinergicUnknownRibavirin, mycophenolic acid, mizoribine, gemcitabineNucleic acid synthesis inhibitorsUnknownCamostat mesylate, K11777, E-64-D, lopinavirProtease inhibitorsCamostat mesylate inhibits TMPSSR2-mediated glycoprotein activation of MERS-CoV and SARS-CoV. K11777 and E-64-D act as attachment inhibitor for both MERS-CoV and SARS-CoV. Lopinavir has been shown to target the main protease (Mpro) of SARS-CoVEmetine, anisomycin, omacetaxine mepesuccinateProtein synthesis inhibitorsUnknownToremifene citrate, tamoxifen citrateSelective estrogen receptor modulatorsUnknownTerconazole and triparanolSterol metabolism inhibitorsUnknown

Vaccine for Coronaviruses {#Sec9}
=========================

Currently, vaccines that can protect against CoV infection are not available. Recently, many groups are involved in vaccine designing using a variety of platforms against CoVs. Some of these approaches have demonstrated effectiveness in animal models. The spike (S) protein present in CoVs acts as a viral antigen and responsible for host--receptor binding and virus internalization and induces robust humoral and cell-mediated responses in humans during infection. The S glycoprotein has been shown to involve in the internalization of other CoVs like SARS by binding to its cellular receptor angiotensin-converting enzyme 2 (ACE2). The S-protein functions in the receptor binding and membrane fusion make it the ideal target for the production of vaccines against CoVs (Wang et al. [@CR55]). Recent experiments have shown that the S-protein vaccine can trigger antibodies to resist virus binding, fusion, and neutralization of SARS-CoV infection. Recently, S-protein-based vaccines such as DNA vaccines, modified vaccinia Ankara (MVA)-based chimeric virus vaccines, subunit vaccines, and virus-like replicon particle (VRP)-based chimeric virus vaccines have been developed, and they demonstrate protective effect against both MERS-CoV and SARS-CoV infections in animal models (Schindewolf and Menachery [@CR46]).

Complementary and Alternative Medicines (CAM) for Coronaviruses {#Sec10}
===============================================================

According to the National Center for Complementary and Integrative Health (NCCIH) of the National Institute of Health (NIH), USA, CAM encompasses various medical methods, such as homeopathy, naturopathy, Ayurveda, medicinal systems, and products originating from traditional medicine. Recently, CAM therapies have shown to be potential therapeutics for the management of virus-associated diseases such as influenza, Japanese encephalitis, hepatitis C, zika, and HIV (Saxena et al. [@CR45]). These medicines also demonstrate efficacy against coronaviruses with minimal reported adverse effects on host cells. Considering the global transmission and fatality rate of SARS-CoV-2 infection, the Government of India, Ministry of Ayush has given recommendations for the use of Indian herbal drugs that practices under the Ayurveda, Homeopathy, and Unani system of medicine for combating coronaviruses (PIB Delhi [@CR41]).

Ayurverdic Medicines for the Treatment of Coronaviruses {#Sec11}
-------------------------------------------------------

Shadanga Paniya is a herbal formulation that mainly comprises *Cyperus rotundus*, *Fumaria indica*, *Vetiveria zizanioides*, *Pterocarpus santalinus*, *Pavonia odorata*, and *Zingiber officinale*). This herbal formulation is recommended for the treatment of symptoms such as high fever, shivering, muscle aches, headache, loss of appetite, dehydration, fatigue, restlessness, excessive thirst, irritability, and burning sensation. In addition, Shadanga Paniya also has antibacterial and antimicrobial activities, and recently, this medicine is recommended by the Ministry of Ayush for the treatment of coronaviruses. Agastya Harityaki is a popular polyherbal Ayurverdic medicine mainly recommended for respiratory problems such as asthma, pneumonia, and chronic bronchitis. The medicine is reported to have antiviral, antibacterial, antifungal, antioxidant, anticarcinogenic, antiaging, antidiabetic, antiulcer, cardioprotective, hepatoprotective, and wound healing properties. Samshamani Vati is used for the treatment of acute to chronic fever and anemia (500 mg twice a day). *Tinospora cordifolia* is the main ingredient and responsible for anti-inflammatory and antipyretic properties of Samshamani Vati. Pratimarsha Nasya (Anu taila/sesame oil) has preventive as well as curative aspect for the treatment of Nasobronchial diseases and enhances the respiratory immunity. The ingredients present in sesame oil are well known for anti-inflammatory, antipyretic, and antibacterial proprieties. Another formulation which comprises Trikatu (Pippali, Marich, and Shunthi) and Tulasi is also recommended by the Ministry of Ayush for the treatment of coronavirus infection in India.

Homeopathic Medicines for the Treatment of Coronaviruses {#Sec12}
--------------------------------------------------------

After the emergence of SARS-CoV-2 in India, the Central Council for Research in Homeopathy (CCRH) has recommended Arsenicum Album 30 as prophylactic medicine against coronavirus infections. It was recommended that one dose of Arsenicum Album 30 should be given daily in empty stomach for 3 days and should be replicated after 1 month on the same schedule in the case of coronavirus infections arising in the population.

Unani Medicines for the Treatment of Coronaviruses {#Sec13}
--------------------------------------------------

The Government of India has suggested a number of Unani medicines such as Sharbat Unnab (10--20 ml), TiryaqArba (3--5 g), TiryaqNazla (5 g), Habb e IkseerBukhar (2 pills), Sharbat Nazla (10 ml), and Qurs e Suaal (2 tablets) recommended twice a day with lukewarm water. In addition, Arq Ajeeb (4--8 drops) and Khamira Marwareed (3--5 g) are also suggested for the better management of disease. Similarly, medicines like RoghanBaboona/Roghan Mom/Kafoori Balm are also recommended for massage on scalp and chest in case of infection. In addition, the Arq extracted from single Unani drugs like *Azadirachta indica* (Margosa), *Swertiachirata karst* (Indian Gentian), *Trachyspermum ammi sprague* (ajowan), *Cichorium intybus* Linn. (common chicory), *Cyperus scariosus* R. Br. (cypriol), *Borage officinalis* Linn. (Borage), and *Artemisia absinthium* Linn. (common sagewort) along with SharbatKhaksi may be used to combat the infection. In the same way, decoction of Unani drugs such as *Cydonia oblonga* (Quince), *Zizyphus Jujube* Linn. (jujubi), Papaver somniferum (khashkhash), *Cordia myxa* Linn. (Assyrian plum), *Cinnamomum zeylanicum* (cinnamon), *Hyoscyamus niger* (bazrulbanj), *Viola odorata* Linn. (sweet violet), *Borago Officinalis* Linn. (borage), *Myrtus communis* (Barg e Moard), *Lactuca sativa* (Tukhm e kahuMukashar), and *Rosa damascene* (GuleSurkh) are also being suggested for conditions like sore throat during infection.

Herbal Medicines Showing Efficacy Against Coronavirus in Cell Culture Model {#Sec14}
---------------------------------------------------------------------------

It is reported that a number of herbal extract of *Anthemis hyaline*, *Acanthopanacis cortex*, *Citrus sinensis*, *Sophorae radix*, *Sanguisorbae radix*, *Nigella sativa*, and *Torilis fructus* inhibit coronavirus replication in vitro (Ulasli et al. [@CR54]; Kim et al. [@CR28]). Similarly, studies have demonstrated that traditionally used medicinal herbal extracts such as *Cimicifuga rhizoma*, *Coptidis rhizoma*, *Phellodendron cortex*, and *Meliae cortex* are also shown to inhibit CoV replication in cell culture model (Kim et al. [@CR27]). Emodin, a chemical constituent of genus Rheum, and Polygonum are also shown to block the binding of SARS-CoV S-protein to ACE2 in a dose-dependent manner (Ho et al. [@CR24]). In the same manner, *Artemisia annua*, *Lycoris radiate*, *Lindera aggregata*, *lycorine*, and *Pyrrosia lingua* also showed antiviral activity against SARS-CoV (Li et al. [@CR34]). In addition, saikosaponins are natural triterpene glycosides (A, B~2~, C, and D) and were tested against HCoV-22E9, and it is found that saikosaponin B~2~ inhibits virus attachment and penetration stage to the host cells (Cheng et al. [@CR14]). In the same way, myricetin and scutellarein act as inhibitor of SARS-CoV helicase. Similarly, theaflavin-3,3-digallate (TF3) is a natural polyphenolic compound and demonstrates antiviral activity via targeting 3C-like proteases of SARS-CoV (Chen et al. [@CR12]). Eupatorium fortune is a herbal medicinal plant belonging to Korea, China, and Asian countries with antibacterial and antioxidant activities and anticancer activity. Recent studies have reported that eupatorium fortune can inhibit a number of RNA viruses including human coronaviruses (Choi et al. [@CR17]). As these herbal drugs demonstrated potential antiviral activity against CoVs, there is an urgent need to establish their effectiveness in humans and approve in a dose-dependent manner from various organizations like Food and Drug Administration (FDA). In the absence of specific antiviral agent or vaccine, the use of complementary and alternative drugs may found to be beneficial during humanitarian emergencies.

Conclusions {#Sec15}
===========

The recent outbreak brought SARS-CoV-2 as global concern and emphasizes the significance of restricting infectious agents at international borders. The risk of SARS-CoV-2 outbreaks depends on the characteristics of the virus, including the ability of the virus to transmit among humans, the seriousness of the disease, and the medical or other interventions available to prevent the transmission of virus, such as vaccines or drugs. Although, ribavirin along with corticosteroids and interferons has been tested in patients with SARS and MARS-CoV infections, but the effectiveness and associated severe adverse effects of this regimen is still not yet confirmed. In addition, a large number of drugs from different classes have been used for the management of symptoms associated with the infection and reported to have antiviral activity against both SARS and MARS-CoV infections in animal and cell culture model. However, the antiviral potential of these repurposing drugs are need to be validated in clinical trials in order to developed broad-spectrum therapy for SARS-CoV-2, SARS-CoV, and MARS-CoV infections.

Future Perspectives {#Sec16}
===================

At present, the control of viral spread is critical in order to restrict the transmission of infection. The effective communication among the various organizations such as government, industry, academic, national, and international bodies is crucial in order to prevent the transmission of infection during outbreaks. In the absence of specific therapeutic agent, the study of pathogenesis of infection is imperative to identify newer targets for designing of novel therapeutic agents for future outbreaks. Similarly, the standardization of various complementary and alternative medicines may prove as safe and potential therapeutic strategies for emerging CoVs.
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